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ABSTRACf 
Eleven uveaI .......... Ml'e lUIIIIyzed usIDg compandve genomIc hybrid-
lzatioD (CGH). 'Ibe most abqndant genetic cbaIJ&es Ml'e lass of cbnmoIome 3, 
O •• lepi ............ of 6p, lass of 6q, ....... dllpIbtIon of Bq. 'Ibe lIIII8IeIIt 
Of&iepi...ttd ..... Im 6p .... Bq Ml'e ~11111d 8qZ4-tqIer. respec> 
dwIy. SeftnI addIdonaI pIns ....... of cbnmoIome...-.. Ml'e repeat. 
edIy oIarwd, Ibe most Inqueot .. beiBg lass of9p (dne cases). MonoIomy 3 
appeand tu be a iIiIII'IrIir tbr dIIary body lnvoIYemmt. 
CGH data weft compared wltb tbe nsuIts of cbromoIome bandIng. Some 
alteratlollS, e.g .. piDs of 6p and loIIes of 6q, weft ob5erved wltb bigber 
fIequenc:ies alter CGH, wbIIe odlen, e.g .. 9p ~ weft deteded onIy by 
CGH. 'Ibe data sagest lOiIIe lImiIarides of c:ytogeDetic: aItenticaB between 
~ and uveaI meIanoma, In putic:uIar, tbe 9p deIetioDs are or Interest 
cIue tu rec:mt repoI1s about tbe locatioD of a putative tumOl'-suppressor gene 
for cutaneous maHgnant meIanoma In tbIs reglon. 
INTRODUCTION 
Uveal melanoma (ciliary body and choroid) is the most common 
primary intraocular tumor in adults with an incidence of six to seven 
cases per one million people per year in North America (1). Tbe 
etiology is unknown. Chemical agents (2), viruses (3), UV radiation, 
trauma, and nevi have been implicated in its development (1). Al-
though uveal melanoma is not considered to be an inherited disorder, 
there are 14 families documented in the world literature with at least 
two members having this disease (1, 4). 
Recently, several cytogenetic analyses of uveal melanomas have 
been reported, demonstrating the occurrence of monosomy 3, 
i(8)(q10), trisomy 8, multiplication of 6p, and a loss of the long arm 
of chromosome 6 in a nonrandom fashion (5-13). Between uveal 
melanoma involving the ciliary body and choroidal melanomas, dif-
ferences in the frequencies of aberrations were observed for chromo-
somes 3 and 8 and accounted for the different clinical behavior of 
tumors at these sites (10). Molecular genetic studies revealed loss of 
alleles on chromosome 3 and multiplication of chromosome 8 alleles 
(14). Immunohistochemistry indicated high level expression of mutant 
p53 (15) and c-Myc protein (16). 
In this study, we investigated 11 uveal melanomas with the recently 
introduced technique of CGHs (11). With CGH, differentially labeled 
tumor and normal DNA are hybridized simultaneously to normal 
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metaphase chromosomes. Regions of gains or losses within the tumor 
DNA can be identified by an increased or decreased color ratio of the 
two fluorochromes used for the detection of hybridized DNA se-
quences along these reference chromosomes (17-23). 
Tbe comparison of the results of CGH and banding analysis re-
vealed some unexpected findings. When compared with chromosome 
aberrations reported for cutaneous melanomas (24-35), our results 
indicate some similarities between cutaneous and uveal melanoma, 
hinting at the involvement of several identical genes. 
MATERIALS AND METHODS 
CUnicai ud Pathological Data. Oinical and histological data of patients 
with uveal melanoma are summarized in Table 1. 
DNA Probes aad LabeIiDg Procedures. Total genomic DNA probes were 
labeled with digoxigenin-ll-dUI'P or biotin-ll-dUI'P using standard Dick-trans-
1ation procedures (36). 1be bJmor DNA was obtained from fresh-frozen material. 
CGH. CGH was done as described previously (18, 20) with minor modi-
ficatiODS. Briefly, 100-200 ng of biotinylated tumor DNA was mixed with the 
same amount of normal male digoxigenin-labeled reference DNA and hybrid-
ized to reference metaphase spreads (46,xy) in the presence of SO jJ.g Cotl-
DNA and SO jJ.g soDicated salmon DNA. Hybridization was a1lowed for 4 to 
5 days. Probe detection was carried out as described (18, 20). 
Digital Image Analysis. Image acquisition and image processing were 
performed as detailed in (18, 20). Briefly, an epifluorescence microscope 
(Zeiss Axiophot) equipped with a cooled, charged coupled device-camera 
(photometrics, Tucson, AZ; Kodak 1400 chip) was used. Using the appropriate 
filter sets, gray level images were taken separately for each f1uorochrome. 
Chromosomes were identified using the f1uorescence banding pattern obtained 
after DAPI staining. m'C and TRITC f1uorescence were specific for the tumor 
and the control genome, respectively. F1uorescence m'C:TRITC pixel-by-
pixel ratio images (Fig. 2, A and B) were calculated as described (18, 20). 
Briefly, a symmetricallook-up table was used for visualization of the pixel-
by-pixel m'C:TRITC ratios. The thresholds could be chosen arbitrarily since 
they were used for the visualization of over- and underrepresented DNA 
segments only. 
The determination of over- and underrepresented DNA segments was done 
by m'C:TRITC average ratio profiles (Fig. 3). These average m'C:TRITC 
ratio images were calculated from at least 10 metaphases and have fixed 
thresholds which were tested by control experiments using normal DNA and 
DNA from cell Iines with known numerical aberratioDS. The centralline in the 
profiles represents the modal f1uorescence ratio value measured for all refer-
ence metaphase spreads. The left and the right lines correspond to the theo-
retical ratio value for a monosomy or trisomy, respectively, in 50% of the cell 
population. These thresholds were tested for sensitivity and specifity in a great 
number of different hybridizatiODS (more than 1(0) made by several experi-
menters. The procedure coDSists of calculation of the medial axis of each 
chromosome within the DAPI image, calculation of F1TC and TRITC profiles 
a10ng individual chromosomes, and as a last step, an averaging of individual 
chromosome ratio profiles from different metaphases. The entire procedure 
will be described in detail e1sewhere.6 
• S. du Manoir, E. Schröck, M. Bentz, M. R. S. JOO5, T. Ried, P. Uchter, and 
T. Cremet. Quantitative analysis of IXIlIlparative genomic hybridization, submitted for 
publication. 
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Table I Clinica/ anti hist%gica/ data 0/ pati~nts with uv~aIlMlonomo intensities allowed the generation of a pixel-by-pixel ratio image 
displayed as a look-up table in Fig. 2A. Blue represents the modal 
fluorescence intensity ratio between the tumor and normal reference 
DNA. Tbus, blue represents equal copy number in the tumor and 
normal reference genome, because both genomes are diploid. Green 
indicates overrepresentation and red underrepresentation in the tumor 
genome. This allows the generation of a copy number karyotype, 
shown in Fig. 2B. Losses of chromosome 3, chromosome arms 6q, 8p, 
and 16q, as weil as the distal part of the short arm of chromosome 9, 
9pter-+p2I, are readily detectable. Chromosome arm 8q is overrep-
resented. An average fluorescence ratio profile calculated for each 
chromosome from 10 metaphase spreads is exemplified in Fig. 3. Tbe 
evaluation of chromo-somal gains and losses was, in all cases, based 
on these ratio profiles. 
Tumor Tumor 
Age basis thickness 
Patient 00. (yrs) Sexo (mm) (mm) 
AM89'"·d 28 M 18.0 11.0 
AMI09'··d 70 M 15.0 12.3 
AM 11 3d 45 M 15.0 8.0 
AMII5d 67 M 14.0 9.0 
AM 145' 31 M 8.0 2.0 
AMI59 65 M 22.0 8.0 
AMI65 79 F 16.0 12.0 
AMI85 66 F 12.0 12.0 
AM 186 52 F 12.0 9.0 
AMI87 50 M 10.0 Unknown 
AM 189 78 F 15.0 10.0 
° F. female; M. male. 
b Ep. epitheloid; Mx. mixed; Sp. spindle. 
C Previously published (see Ref. 7). 
d Previously published (see Ref. 14). 
, Previously published (see Ref. 10). 
Cell Ciliary body 
typeb involvement 
Sp Yes 
Sp Yes 
Mx Yes 
Ep Yes 
Mx No 
Sp Yes 
Mx Yes 
Ep No 
Mx No 
Mx No 
Ep No 
Infilllalion 
of scleral 
lamellae 
Yes 
Yes 
No 
Unknown 
No 
Yes 
No 
No 
No 
Yes 
Unknown 
A survey of all CGH results from uveal tumors of 11 patients is given 
in Fig. 4. Losses of genetic material are represented by verticallines on 
the left sille of each chromosome, whereas lines on the right sille repre-
sent gains. Case numbers are provided on the top of each line to facilitate 
the identification of changes in individual cases. 
Cytogenetie Analyses. Culturing and cell processing was perforrned as 
described (7). Culturing time depended on the proliferation activity and varied 
for each tumor, ranging from I to 8 days (Table 2). 
Tbe most frequent finding was a gain of DNA segments on 
chromosome 8 (7 of 11) with 8q24-+qter as the smallest overrep-
resented segment found (AMI45). Tbe second most common find-
ing was a gain of 6p material (6 of ll) with 6pter-+p21 as the 
smallest overrepresented segment (AMI86). Loss of chromosome 
3 and loss of chromosome arm 6q were found five times each. 
Additional findings included loss of9p (3 of ll; AM1l3, AMI59, 
and AM165), loss of Ilq23-+qter (2 of 11; AM89 and AM145), 
loss of 16q (2 of 11; AMI59 and AM165), and gain of chromo-
some 17 (2 of 11; AMI09 and AMI65). Copy number changes of 
several other chromosomes and chromosomal subregions were 
noticed once, i.e., loss of Ip (AMI65), gain of Iq (AMI45), gain 
of 3q25-+qter (AMI87), gain of 7p21-+pter (AMI45), gain of 
chromosome 9 (AMI85), gain of IIp (AMI87), loss of 12p 
(AMI86), and gains of the chromosomes 14 (AMI09), 21 
(AM185), and 22 (AM165). 
Molecular Genetie Methods. Southem blot analysis of blood and tumor 
DNA. densitometric analysis. and enzymatic DNA amplification were done as 
described previously (14). The probe pEFD64.2 was obtained through the 
American Type Culture Collection. It detects a highly informative variable 
number of tandem repeat polymorphism at the D3S46locus (14). 
RESULTS 
CGH 
CGH results of tumor AMI59 are exemplarily shown in Figs. 1-3. 
Comparison of Banding Analysis and CGH nata 
Tbe fluorescence DAPI banding pattern used for chromosome iden-
tification is shown in Fig. IA. Tbe FITC and TRITC fluorescence 
Cytogenetic banding results could be obtained for 8 of the II tumor 
sampies (7, Table 2C ), revealing multiple clonal aberrations (Table 2). 
Patient 
00. 
AM 159'" 
AM I 8?' 
AM 1 89'" 
CullUre 
time 
(days) 
8 
5 
4 
1-4 
1-3 
3-5 
~7 
Aberrant 
karyotype 
(n) 
3 
2 
19 
12 
6 
5 
19 
21 
3 
2 
28 
3 
11 
G Previously published (see Ref. 7). 
b Previously published (see Ref. 14). 
Table 2 CU/lUn tUM anti abnormal chromosomo/ jindings 
Clonal aberrations 
47 .XY .add(6)(q27).dup(8)(q2Iqter). +dup(8)(q2Iqter) 
47,xY.add(4)(pI6).add(6)(q27).dup(8)(q2Iqter).+dup(8)(q2Iqter) 
47,x. - Y ,add(4)(pI6).add(6)(q27).dup(8)(q2Iqter). +dup(8)(q2Iqter). +mar 
47.X. - Y ,add(4)(pI6).del(6)(qI3).dup(8)(q2Iqter). +dup(8)(q2Iqter). +mar 
46.XY. +der(8;21)(q lO;q 10).add( 11 )(q25). - 21 
46,xy. +der(8;21)(qlO;qI0).add(1l)(q25).del(1l)(q23).-21 
46.XY.del(6)(q 13q26). +der(8;21 )(qIO;qIO),add( 11 )(q25). - 21 
4S,x. - Y.die( I ;6)(q44;q 12). +del(6)(q22).dup(8)(q2?3qter).der(16)t( I ;6;16)( 16pter ..... I6q24:: Iq 11--> Iq44::6q 12-->6pter) 
45,xy. - 3. +der(8;21)(q 10;q 1O),add( 12)(p?). -14.der( 19)1( 14; 19)(qI2;p\3) 
46.idem. + 12 
45.XX,r(6)(p2S ..... q?).add( I O)(p?).I6qh + • - 20,i(22)(q I 0) 
46.XY.dup(3)(q25qter).add(6)(q?).der(6)l(6;8)(p25;qI3),add(II)(pIS).add(20)(qI3.3) 
73-87.XXX.<4n>.-X. -I. -I. -2. - 3. - 3. -9. -10. -11. -12. -15. -19. +2r. + 3mar[cpll) 
C G. Prescher. N. Bomfeld, W. Friedrichs. S. Seeber. and R. Becher. Cytogenetics of twelve new cases of ureal melanoma and patterns of nonrandom anomalies and isochrome 
formation. Cancer Gene\. Cytogenet .• in press. 
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A 
B 
AM 159 
2 3 
6 7 8 9 10 11 12 
13 14 15 16 17 18 
19 20 21 22 x y 
Fig. 1. CGH analysis of tumor AM1S9. A, DAPI staining of normal me1apbasc 
cbromosomcs used for cbromosome identification in CGH experimenI displayed in Fig. 2. 
B, example of a G-banding karyotype of tumor AMIS9. The 1055 of cbrolllOllOlllC Y is not 
c1onal. 
Chromosome numbers were within the diploid range, except for case 
AM189 which revealed hypotetraploid cbromosome counts. 
For some tumors, a close correlation was observed between cyto-
genetic and COH data, but marked differences were also noted. For 
example, compare the O-banding karyotype of tumor AM159 in Fig. 
1B with the "copy number karyotype" in Fig. 2B or the average ratio 
profile in Fig. 3. Banding analysis and COH revealed loss of chro-
mosome 3. However, striking differences were noted for chromo-
somes 6, 8, 9, and 16. Banding analysis did not show loss of cbro-
mosome 6 material, whereas COH demonstrated a loss of the long arm 
of chromosome 6. Similary, banding analysis did not suggest loss of 
the short arm of cbromosome 8, wbich was revealed by COH. All 
metaphase spreads evaluated by banding analysis showed two normal 
chromosomes 9 and 16; however, COH showed loss of 9pter--p21 
and loss of 16q. Banding analysis showed the occurrence of 
two additional marker chromosomes, +der(8;21XqlO;qlO) and 
+add(12)(p?). The first marker cbromosome should result in an 
overrepresentation of chromosome 21 material, wbich was not noted 
with COH. The second marker cbromosome should yield an overrep-
reseotation of chromosome 12 and additional overrepresentation of 
DNA segments, wbicb could not be furtber identified by banding 
analysis. However, COH did not reveal additional cbromosome 12 
material. Since tbe long arm of chromosome 8 was the only overrep-
resented region in COH analysis, one could speculate that part of the 
+add(12)(p?) marker cbromosome could contain chromosome 8 ma-
terial. Similar striking differences were found for the other tumors. 
Fig. 2. A, ßuorescence ratio image of the same me1apbue spread as in Fig. lA after 
CGH witb tumor DNA AM1S9 and normal male rcfercncc DNA. A look-up 1able 
visualizes tbe pixel-by-pixel mC:TRITC ratios. BIllt!, balanced s1ate of chromosome 
material in the rumor and normal rcfercnce genome. Gr«1I, overrcprcsen1ation in the 
tumor genome. Red, underrcpresen1ation in the rumor genome. The image reveals the Bq 
ums as overrcprcsented DNA segments. Other chromosomes or chromosome segments 
arc underrcprcsented: chromosomes 3, 6q, 8p, 9pter~p21 . 16q, and X (male patient). B, 
pixel-by-pixel ratio image of (A) sorted by chromosomes to facili1ale tbe identification of 
numerica1 abnormalities. 
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1 2 3 4 5 
13 14 15 16 17 18 
20 21 22 y 
x 
Fig. 3. Average ratio profile of tumor AM1S9. For detaiIs, see lext and Refs. 18 and 20. 
Ratio profiles alODg tbe individual clJroDlOllOllleS are sbown OD tbe rigllt side of eacb 
cbromosome. Left, middJe, and rigllt verticallanu represent tbe lower, middle, and upper 
tbreshold of tbe normal range. Due to tbe suppression witb COII DNA fraction, tbe 
beteroclJromatic blocks (in particuIar tbe centromeric or par&centromeric regions of 
clJromosomes I, 9, and 16 and tbe p arms of an ac:rocentric chromosomes) yield unreliable 
ratio values and are excludcd from evaluation. F1uorescence values defining tbe normal 
range corrcspood to tbe tbresbold values of Pig. 2A and 18. 
AMI86. Banding analysis revealed several marker chromosomes 
such as r(6X6pter-+q?) and add(10XP?). Unequivocal findings were 
loss of chromosome 20 and gain of the long arm of chromosome 22 
due to an i(22XqlO). CGH revealed amplification of 6p and losses of 
12p and the X chromosome. 
AMIS7. Gain of 3q25-+qter, Bq, and loss of 6q were observed by 
both methods, but CGH revealed addition gains in 6p and 11p. 
AMIS9. Banding analysis revealed a hypotetraploid tumor with 
disomies or trisomies, respectively, of chromosomes 1, 2, 3, 9,10,11, 
12, 15, and 19. Additionally, several marker chromosomes were 
observed. CGH found chromosomes 1, 2, 3, and 11 underrepresented 
but not the other chromosomes. 
Molec:ular GeDetic: Results 
Tumor and normal DNAs from five patients were studied using 
DNA polymorphisms on chromosome 3. The results of three patients 
(AM89, AMI09, and AM113) were published previously (14). Con-
stitutional heterozygosity was maintained in the tumor DNA from 
case AM145 but was lost for case AMI59. Copy number changes of 
Bq in tumor DNA for AM89, AM109, and AM113 were also pub-
lished in (14). Allioss of heterozygosity studies were in full accord-
ance with the findings of CGH. 
DISCUSSION 
Remarkable differences were noted between the results of banding 
analysis and CGH. Several reasons can be attributed to these differ-
ences. In contrast to banding analysis, CGH does not give information 
on a single cell basis but reveals only genetic imbalances which are 
present in the majority of the cells (>60%).6 Chromosome banding 
analyses were carried out after in vitro cultivation. Cultural artifacts, 
Le., growth advantages resulting in a clonal shift during culture, may 
yield cytogenetic results which are not representative for the in vivo 
situation of the tumor. In contrast, CGH was performed with DNA 
directly prepared from tumor materials. 
Previously, a very close concordance between CGH and chromo-
some banding was observed when tumor celllines were subjected to 
both methods (17, 18, 20). Additionally, when comparing average 
fluorescence ratios with interphase cytogenetic data performed on 
AM89. Overrepresentation of chromosome 8 was found by band- uncultured nuclei of tumor sampies from which the DNA was ob-
ing analysis and CGH. However, losses of 6q and the Y chromosome, tained for CGH, we found a linear correlation between the fluores-
as suggested by banding analysis, were not found with CGH. Instead, cence ratios and the average signal number (21). Thus, we do not 
gain of 6p and loss of llq23-+qter were identified with CGH. The attribute the discrepancies between the results of banding analysis and 
gain of 6p material could be attributed to a marker chromosome CGH to inconsistencies of the CGH approach per se. 
observed in banding analysis, the DNA content of which could not be It is also notable that CGH detected some aberrations with a higher 
identified unequivocally. frequency than banding analysis. For example, gain of 6p was diag-
AMI09. A gain of 8q and loss of 6q were found with banding nosed in 14% (1 of 7) with banding analysis and in 46% (5 of 11) with 
analysis and CGH. Again, banding analysis showed a marker chro- CGH; loss of 9p was not found in any karyotype but in some 30% (3 
mosome yielding additional DNA material, the origin of which could of 11) of all cases with CGH. 
not be clarified. CGH revealed DNA amplifications of chromosome The most commonly involved chromosomes detected by CGH were 
arm 6p and chromosomes 14 and 17. Adeletion of 11q23-+qter as chromosomes 3, 6, and 8 (Fig. 4). This is consistent with aseries of 
found in banding analysis was not detectable with CGH. previous studies performed with chromosome banding (5-9, 11-13). 
AMI4S. Cytogenetic analysis showed overrepresentations of the All tumors with loss of chromosome 3 material showed loss of the 
long arms of chromosomes 1 and 6 and the distal part of the long arm entire chromosome 3. Partial deletions of chromosome 3 which are a 
of chromosome 8, Bq2?3-+qter. All of these overrepresentations could common event, e.g., in nonpapillary renal cell carcinoma (37) or lung 
be verified with CGH. Additionally, DNA multiplication was found cancer (38), were not detected. These differences may indicate that 
on 7pter-+p21. Losses indicated by banding analysis included the several genes located on both arms of this chromosome may be 
long arm of chromosome 6 and the Y chromosome. The loss of 6q was involved in uveal melanoma, while genes involved in renal cell 
also noted with CGH, and additionally, loss of llq23-+qter was carcinoma and lung cancer may be restricted to the short arm. 
found. CGH did not reveal loss of the Y chromosome. The smallest overrepresented region on 6p was 6pter-+p21 and 
AMI85. The only finding in banding analysis was a marker chro- 8q24-+qter on Bq. While no candidate oncogene is known for 6p at 
mosome, add(21Xq22). CGH detected gain of chromosomes 9 and 21. present, the region Bq24-+qter harbors the c-myc oncogene. Using 
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monoclonal antibodies against the c-myc product, strong cytoplasmic 
staining has been reported for uveal melanoma. implying an involve-
ment of this gene in cellular prolüeration (16). Putative suppressor 
genes on 6q, a target of frequent deletion, have also not yet been 
identified. 
No regional high-level amplifications were observed in aII uveal 
melanomas analyzed. This correlates weil with cytogenetic results 
where homogenously staining regions or double-minute chromosomes 
were never described (5-9, 11-13). 
Cytogenetic differences for uveal melanomas with and without 
involvement of the ciliary body were reported and attributed to the 
different clinical behavior of these tumors (10). The interpretation of 
our present study has to be performed with caution due to the small 
number of cases, but it is interesting to note that 6p gains, 6q losses, 
and 8q gains occurred in both types of tumors in 50% or more of all 
cases. In contrast, losses of chromosome 3 (with the exception of the 
hypotetraploid tumor AM189), 9p, and 16q, and gains of chromosome 
17 were observed in uveal melanomas involving the ciliary body only. 
Comparison with the literature (5-9, 11-14) indicates that chromo-
some 3 loss may provide a highly specific marker for ciliary body 
uveal melanoma and may serve to identify patients with poor prog-
nosis (10). In our study, CGH in AMl15 showed loss of chromosomes 
3 and Y only. In agreement with an observation of Wiltshire et al. 
(12), who reported on a patient with ciliary body uveal melanoma 
showing loss of chromosome 3 as the sole visible cytogenetic aber-
ration, it is reasonable to speculate that loss of chromosome 3 may be 
the first cytogenetic "hit" in the multistep pathogenesis of ciliary body 
uveal melanoma. 
Uveal and cutaneous malignant melanomas have often been con-
sidered tumor entities with distinctly different genetic mechanisms. 
This was based on the fact that cytogenetic alterations of chromo-
somes 1, 7, 9, and 11 were frequently observed in cutaneous mela-
nomas but rarely observed for uveal melanomas (24-34; reviewed in 
Ref. 35). On the other hand, overrepresentation of 6p (24, 25) and loss 
of 6q (26-28) were frequently noted in both entities. Recently, the 
locus for familial cutaneous melanoma was assigned to chromosome 
9p21 by Iinkage analysis and physical mapping (39-42). This mela-
noma susceptibility gene supposedly acts as a tumor suppressor gene 
(42). Molecular studies showed that loss of heterozygosity on 9p was 
an early change in cutaneous melanoma (43). A1though the cytoge-
netic differences between cutaneous and uveal melanoma are signü-
icant, CGH results indicate some cytogenetic similarities, suggesting 
the possible involvement of several identical genes. This conclusion is 
based on: (a) the fact that 6p gains and 6q losses were found with 
higher frequency with CGH than with chromosome banding analyses; 
and (b) the observation of 9p losses in some 30% by CGH. This is a 
much higher percentage than the reported alterations of 9p in the 
literature obtained by banding analysis (5-13) of some 8% (6 of 71 
cases in Refs. 8, 11, 12, and 13). A possible explanation of this 
discrepancy could be provided by the explanation that tumor cells 
with 9p loss have a selective disadvantage during culture. AM159 
provides a case in point where banding analyses revealed two entirely 
normal chromosomes 9, while CGH revealed a 9p loss (compare Fig. 
1B with Figs. 2 and 3). Thus, we speculate that the number of 9p 
losses detectable in uveal melanomas in vivo may be considerably 
higher than in tumors cultured in vitro and should be considered 
as a nonrandom cytogenetic change in both cutaneous and uveal 
melanomas. 
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